HLS Therapeutics Inc.

TSX:HLS Stock Report

Market Cap: CA$155.1m

HLS Therapeutics Management

Management criteria checks 2/4

HLS Therapeutics' CEO is Craig Millian, appointed in May 2023, has a tenure of 2.58 years. total yearly compensation is $1.35M, comprised of 45.8% salary and 54.2% bonuses, including company stock and options. directly owns 0.04% of the company’s shares, worth CA$62.00K. The average tenure of the management team and the board of directors is 5.1 years and 2.8 years respectively.

Key information

Craig Millian

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage45.84%
CEO tenure2.6yrs
CEO ownership0.04%
Management average tenure5.1yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target

Nov 16
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
User avatar

Vascepa Sales In Canada And Cost Cuts Will Transform Prospects

Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.

Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?

Oct 26
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?

Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now

Sep 28
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now

Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results

May 12
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results

After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar

Apr 14
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar

Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt

Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt

Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be

Nov 16
Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be

Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt

Sep 13
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt

Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?

May 05
Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?

HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05

Apr 05
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05

HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05

Mar 20
HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05

HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05

Nov 30
HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05

Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term

Nov 11
Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term

We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt

Sep 14
We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt

HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05

Aug 15
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05

HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05

Jul 14
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05

HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05

Jun 23
HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05

HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

Jun 08
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

May 25
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05

CEO Compensation Analysis

How has Craig Millian's remuneration changed compared to HLS Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$15m

Mar 31 2025n/an/a

-US$18m

Dec 31 2024US$1mUS$617k

-US$20m

Sep 30 2024n/an/a

-US$22m

Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$1mUS$381k

-US$28m

Compensation vs Market: Craig's total compensation ($USD1.35M) is above average for companies of similar size in the Canadian market ($USD161.03K).

Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.

CEO

Craig Millian (57 yo)

2.6yrs
Tenure
US$1,346,286
Compensation

Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...

Leadership Team

NamePositionTenureCompensationOwnership
Craig Millian
CEO & Director2.6yrsUS$1.35m0.040%
CA$ 62.0k
John Hanna
CFO & Non-Independent Director1.9yrsUS$621.88k0.026%
CA$ 39.7k
Jason Gross
Vice President of Scientific Affairs11.5yrsUS$340.16k0.16%
CA$ 246.5k
Ryan Lennox
Senior VP of Legal7.6yrsUS$475.23k0.0016%
CA$ 2.5k
Brian Walsh
Chief Commercial Officer2.5yrsUS$618.41k0.0038%
CA$ 6.0k
Dave Mason
Investor Relations Officerno datano datano data
David Spence
VP & Corporate Controller7.9yrsno datano data
5.1yrs
Average Tenure
57yo
Average Age

Experienced Management: HLS's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Craig Millian
CEO & Director2.6yrsUS$1.35m0.040%
CA$ 62.0k
John Hanna
CFO & Non-Independent Director2.5yrsUS$621.88k0.026%
CA$ 39.7k
John Welborn
Independent Chairman of the Board4.5yrsUS$165.00k0.45%
CA$ 700.8k
Christine Elliott
Independent Directorless than a yearno datano data
Rodney Hill
Independent Director7.8yrsUS$120.00kno data
Norma Beauchamp
Independent Director4.5yrsUS$110.48k0.0016%
CA$ 2.5k
Kyle Dempsey
Independent Director3.1yrsUS$112.98k0.0056%
CA$ 8.7k
Christian Roy
Independent Director2.5yrsUS$107.50kno data
2.8yrs
Average Tenure
58.5yo
Average Age

Experienced Board: HLS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/01 06:21
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HLS Therapeutics Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
George UlybyshevClarus Securities Inc.